Iranian Journal of Virology
مجله ویروس شناسی ایران
Iran J Virol
Medical Sciences
http://journal.isv.org.ir
1
admin
1735-5680
2588-5030
10.21859/isv
en
jalali
1398
3
1
gregorian
2019
6
1
13
1
online
1
fulltext
en
The Indinavir Derivate as a Novel Pharmacophore for Treatment of HTLV-1 Viral Infections
عمومى
General
پژوهشي
Original article
<div><strong>Background and Aims:</strong> Human T-lymphotropic virus type 1 (HTLV-1), is as a type C retrovirus, which was first isolated from a patient with Adult T-cell leukemia/lymphoma (ATLL). Approximately 10-20 million people are infected by HTLV-1 virus worldwide, but only 5-10% of them develop clinical manifestations such as Acute-T lymphoma (ATL), HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP), uveitis, and infective dermatitis. Indinavir was the first protease inhibitor used for treating HIV-1. It has some activity on HTLV-1, but it is not fully able to inhibit the HTLV-1 protease. Nowadays, design and construction of novel pharmacophore compounds can serve as an appropriate replacement for Indinavir. <br>
<strong>Materials and Methods:</strong> In the present research, we used bioinformatics studies, to evaluate the potential role of four novel pharmacophres with inhibitory function on HTLV-1 protease, so called KMI pharmacophores (Keikha Modified Indinavir).<br>
<strong>Results:</strong> After a detailed structural analysis of each of them, it seems all four designed phamacophores, (especially KMI-3) could be more effective on HTLV-1 protease than Indinavir.<br>
<strong>Conclusions: </strong>According to exact in silico evaluations of each four pharmacophores, KMI-3 demonstrated a potential for its use on treatment of HTLV-1 infections. </div>
HTLV-1, Protease, Indinavir, Molecular docking
16
23
http://journal.isv.org.ir/browse.php?a_code=A-10-224-4&slc_lang=en&sid=1
masoud
youssefi
youssefim@mums.ac.ir
10031947532846007038
10031947532846007038
No
Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Antimicrobial Resistance Research center Mashhad University of Medical Sciences, Mashhad, Iran.
kiarash
ghazvini
ghazvinik@mums.ac.ir
10031947532846007039
10031947532846007039
No
Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Antimicrobial Resistance Research center Mashhad University of Medical Sciences, Mashhad, Iran.
Carlos
Brites
abba@gmail.com
10031947532846007040
10031947532846007040
No
LAPI, Laboratório de Pesquisa em Infectologia, Department of Medicine, Complexo Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Salvador, Brazil.
Mohsen
Karbalaei
abba@gmail.com
10031947532846007041
10031947532846007041
No
Department of Microbiology and Virology, School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran
masoud
keikha
masoud.keykha90@gmail.com
10031947532846007042
10031947532846007042
Yes
Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Antimicrobial Resistance Research center Mashhad University of Medical Sciences, Mashhad, Iran.